Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2104-2114

  Reddy, Joseph A ^a   Dorton, Ryan ^a   Bloomfield, Alicia ^a   Nelson, Melissa ^a   Vetzel, Marilynn ^a   Guan, John ^a   Leamon, Christopher P ^a  

^a Endocyte Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DESACETYLVINBLASTINE HYDRAZIDE; DOCETAXEL; DOXORUBICIN; HYDRAZIDE DERIVATIVE; IRINOTECAN; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VINDESINE; VINTAFOLIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FOLIC ACID; TAXOID; VINCA ALKALOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DBA MOUSE; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HELA CELL LINE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FOLIC ACID; HELA CELLS; HUMANS; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, NUDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; TAXOIDS; TOPOTECAN; TREATMENT OUTCOME; VINCA ALKALOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898963005     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2423     Document Type: Article

References (31)

1. Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400-6.
2. D'Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L, et al. Folate receptor-alpha expression in resectable hepatic colorectal cancer metastases: patterns and significance. Mod Pathol 2011;24: 1221-8.
3. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8.
4. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43.
5. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
6. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007;121:938-42.
7. Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res 2008;28:3567-72.
8. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338: 284-93.
9. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 2008;9:1277-86.
10. Low PS, Antony ACe. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004;56:1055-231.
11. Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor-positive tumors. Curr Pharm Biotechnol 2005;6:131-50.
12. Reddy JA, Leamon CP, Low PS. Folate-mediated delivery of protein and peptide drugs into tumors. In:Torchilin V, editor. Delivery of protein and peptide drugs in cancer. London, UK: World Scientific/Imperial College Press; 2006. p. 183-204.
13. Reddy JA, Leamon CP. Folate receptor targeted cancer chemotherapy. In:JackmanAL, LeamonCP, editors. Targeted drug strategies for cancer and inflammation. London, UK: Springer Science; 2011. p. 135-50.
14. Leamon CP, Reddy JA, Klein PJ, Vlahov IR, Dorton R, Bloomfield A, et al. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther 2010;336:336-43.
15. Reddy JA, Dorton R, Dawson A, Vetzel M, Parker N, Nicoson JS, et al. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm 2009;6:1518-25.
16. Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, et al. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue. Cancer Res 2008; 68:9839-44.
17. Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, et al. Folate receptor-specific antitumor activity of EC131, a folate- maytansinoid conjugate. Cancer Res 2007;67:6376-82.
18. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42.
19. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Parker N, Nicoson JS, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugatesEC140 and EC145. Int J Cancer 2007;121:1585-92.
20. Leamon CP, Reddy JA, Vlahov IR, Westrick E, Dawson A, Dorton R, et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol Pharm 2007;4:659-67.
21. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49:1467-76.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
23. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639-42.
24. Naumann RW, Morris R, Harb WA, Micha J, Sutton G, Dinh T, et al. EC-FV-02: a phase II study of EC145 in patients with advanced ovarian cancer [abstract]. In: Proceedings of the 16th International Meeting of European Society of Gynaecological Oncology; 2009 Oct 11-14; Belgrade, Serbia: ESGO; 2009. Abstract nr #A-171- 0006-01181.
25. Vlahov IR, Santhapuram HK, Kleindl PJ, Howard SJ, Stanford KM, Leamon CP. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006; 16:5093-6.
26. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
27. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008;68:771-89.
28. Escobar PF, Rose PG. Docetaxel in ovarian cancer. Expert Opin Pharmacother 2005;6:2719-26.
29. Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin 2009; 25:639-51.
30. Wethington SL, Wright JD, Herzog TJ. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 2008;8:819-31.
31. Sorensen P, Hoyer M, Jakobsen A, Malmstrom H, Havsteen H, Bertelsen K. Phase II study of vinorelbine in the treatment of platinumresistant ovarian carcinoma. Gynecol Oncol 2001;81:58-62.